A new wave of lab-built “evolution engines” is emerging for making asymmetric biocatalysts—enzymes that can reliably produce one molecular mirror image over the other. In a viral report spanning advanced screening and synthetic biology, researchers describe how enantioselective biosensors can act as a filter during directed evolution, accelerating the search for biocatalysts with improved performance.
The core idea is straightforward but powerful: instead of waiting for activity readouts that often ignore stereochemistry, the team uses biosensors that translate enantiomer preference into a measurable signal. When a microbial library of enzyme variants is tested, the biosensor response encodes which enantiomer the pathway favors, allowing researchers to distinguish “chemically active” from “stereochemically correct” candidates.
Technically, the approach couples genotype-to-phenotype evaluation with stereospecific readouts. Candidate variants are expressed in cells, fed substrates, and monitored through sensor outputs that reflect binding or recognition events tied to enantiomer formation. Because the signal is tied to chirality—not merely product quantity—the selection pressure becomes explicitly stereochemical.
This strategy addresses a longstanding bottleneck in biocatalyst engineering. Traditional assays can be slow, labor-intensive, or dependent on downstream chiral chromatography, which limits how many variants can be iterated. By contrast, biosensors enable higher-throughput screening and can be run in formats compatible with iterative cycles of mutation and selection.
The researchers also emphasize the importance of sensor calibration and dynamic range, since subtle shifts in enantiomeric excess must be captured reliably to guide evolution. In practice, sensor performance defines the sensitivity of selection, shaping which mutations survive to the next round.
Asymmetric biocatalysts are central to greener chemical manufacturing, particularly for pharmaceuticals and fine chemicals where chirality often determines therapeutic efficacy. Improved enzymes can replace harsher catalysts and reduce waste, making stereocontrolled synthesis more sustainable.
Overall, the study reframes enzyme evolution as an information problem: the “winning” variants are those that not only act, but act with the right handedness. With enantioselective biosensors turning stereochemistry into a real-time signal, the path to tailored catalysts may become faster, more automated, and more scalable.
In the coming years, expect biosensor-guided evolution to expand beyond chirality alone—potentially incorporating other molecular features such as substrate specificity, pathway flux, or toxicity. For now, this work highlights a compelling route to evolve asymmetric biocatalysts where selection is guided by the mirror-image outcome itself.
Subject of Research: Enantioselective biosensors for directed evolution of asymmetric biocatalysts.
Article Title: Using enantioselective biosensors to evolve asymmetric biocatalysts.
Article References: d’Oelsnitz, S., Kim, W., Zhao, N.N. et al. Using enantioselective biosensors to evolve asymmetric biocatalysts. Nat Chem Biol (2026). https://doi.org/10.1038/s41589-026-02275-1
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41589-026-02275-1
